|  |
Financial Snapshot For September 2005
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| HUMAN GENOME SCIENCES |
$13.59 |
88% |
25% |
$1,777 |
$510 |
$505 |
$1,771 |
$1.6 |
-$224 |
2.3 |
Dec-93 |
4.5 |
$3.00 |
$176 |
| INCYTE CORP. |
$4.70 |
42% |
-51% |
$392 |
$382 |
$350 |
$360 |
$0.8 |
-$101 |
3.8 |
Nov-93 |
2.5 |
$1.88 |
$47 |
| MILLENNIUM PHARMACEUTICALS |
$9.33 |
68% |
-32% |
$2,879 |
$565 |
$190 |
$2,504 |
$1.6 |
-$176 |
3.2 |
May-96 |
3.1 |
$3.00 |
$273 |
| MYRIAD GENETICS |
$21.86 |
84% |
28% |
$675 |
$107 |
$0 |
$568 |
$1.1 |
-$40 |
2.7 |
Oct-95 |
2.4 |
$9.00 |
$163 |
| OSCIENT PHARMACEUTICALS |
$2.12 |
54% |
-40% |
$163 |
$94 |
$175 |
$244 |
$3.9 |
-$87 |
1.1 |
Feb-82 |
0.2 |
$11.00 |
$90 |
| 1st Generation Genomics Average |
|
67% |
-14% |
$1,177 |
$332 |
|
$1,090 |
$1.8 |
-$126 |
2.6 |
|
2.6 |
|
|
| 1st Generation Genomics Median |
|
68% |
-32% |
$675 |
$382 |
|
$568 |
$1.6 |
-$101 |
2.7 |
|
2.5 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| AFFYMETRIX |
$46.23 |
77% |
51% |
$2,951 |
$292 |
$120 |
$2,780 |
$3.2 |
na |
na |
Jun-96 |
6.2 |
$7.50 |
$287 |
| CALIPER LIFE SCIENCES |
$7.03 |
83% |
0% |
$216 |
$40 |
$0 |
$177 |
$0.4 |
-$17 |
2.4 |
Dec-99 |
0.4 |
$16.00 |
$333 |
| CEPHEID |
$7.39 |
65% |
-14% |
$315 |
$50 |
$20 |
$285 |
$1.6 |
-$14 |
3.5 |
Jun-00 |
1.2 |
$6.00 |
$158 |
| CIPHERGEN BIOSYSTEMS |
$1.85 |
39% |
-53% |
$66 |
$16 |
$29 |
$80 |
$0.2 |
-$36 |
0.4 |
Sep-00 |
0.1 |
$16.00 |
$417 |
| COMBIMATRIX CORP. |
$1.66 |
38% |
-53% |
$52 |
$13 |
$0 |
$39 |
$0.7 |
-$15 |
0.8 |
na |
na |
na |
na |
| COMPUGEN LTD |
$3.31 |
51% |
-35% |
$92 |
$17 |
$0 |
$75 |
$0.4 |
-$13 |
1.3 |
Sep-00 |
0.3 |
$10.00 |
$0 |
| ILLUMINA |
$12.81 |
86% |
117% |
$520 |
$37 |
$0 |
$482 |
$13.4 |
-$74 |
0.5 |
Jul-00 |
0.8 |
$16.00 |
$515 |
| NANOGEN |
$3.21 |
40% |
-16% |
$154 |
$25 |
$2 |
$131 |
$1.0 |
-$39 |
0.6 |
Apr-98 |
0.3 |
$11.00 |
$197 |
| ORCHID CELLMARK |
$8.50 |
59% |
6% |
$208 |
$28 |
$0 |
$181 |
$0.4 |
-$7 |
3.8 |
May-00 |
1.1 |
$8.00 |
$263 |
| SEQUENOM |
$0.96 |
53% |
1% |
$39 |
$17 |
$6 |
$28 |
$0.1 |
-$24 |
0.7 |
Feb-00 |
0.0 |
$26.00 |
$609 |
| TRANSGENOMIC |
$1.00 |
61% |
-14% |
$34 |
$2 |
$9 |
$41 |
$0.2 |
-$4 |
0.4 |
Jul-00 |
0.1 |
$15.00 |
$317 |
| Genomic Supply Average |
|
59% |
-1% |
$422 |
$49 |
|
$391 |
$2.0 |
-$24 |
1.4 |
|
1.1 |
|
|
| Genomic Supply Median |
|
59% |
-14% |
$154 |
$25 |
|
$131 |
$0.4 |
-$16 |
0.8 |
|
0.4 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| ARENA PHARMACEUTICALS |
$9.90 |
99% |
130% |
$350 |
$151 |
$0 |
$199 |
$0.7 |
-$64 |
2.4 |
Jul-00 |
0.6 |
$18.00 |
$394 |
| CELERA GENOMICS GROUP |
$12.13 |
82% |
4% |
$903 |
$659 |
$0 |
$244 |
$0.3 |
-$66 |
na |
Feb-00 |
0.1 |
$225.00 |
na |
| CURAGEN CORP. |
$4.95 |
62% |
-10% |
$254 |
$285 |
$226 |
$195 |
$0.6 |
-$63 |
4.5 |
Mar-98 |
0.9 |
$5.75 |
$143 |
| DECODE GENETICS |
$8.39 |
79% |
11% |
$458 |
$177 |
$159 |
$439 |
$1.1 |
-$53 |
3.3 |
Jul-00 |
0.5 |
$18.00 |
$818 |
| EXELIXIS |
$7.65 |
78% |
-5% |
$586 |
$234 |
$147 |
$499 |
$0.9 |
-$39 |
6.0 |
Apr-00 |
0.6 |
$13.00 |
$520 |
| GENAISSANCE PHARMACEUTICALS |
$1.39 |
43% |
-56% |
$49 |
$1 |
$7 |
$56 |
$0.5 |
-$17 |
0.1 |
Aug-00 |
0.1 |
$13.00 |
$288 |
| GENE LOGIC |
$4.89 |
83% |
31% |
$155 |
$99 |
$1 |
$57 |
$0.1 |
-$10 |
9.6 |
Nov-97 |
0.6 |
$8.00 |
$109 |
| ICORIA INC. |
$0.25 |
26% |
-47% |
$10 |
$14 |
$6 |
$2 |
$0.0 |
na |
na |
May-00 |
0.0 |
$7.00 |
$177 |
| LARGE SCALE BIOLOGY CORP. |
$0.83 |
55% |
-14% |
$27 |
($3) |
$5 |
$35 |
$0.5 |
-$17 |
na |
Aug-00 |
0.0 |
$17.00 |
$388 |
| LEXICON GENETICS |
$3.97 |
50% |
-40% |
$253 |
$62 |
$37 |
$229 |
$0.4 |
-$59 |
1.0 |
Apr-00 |
0.2 |
$22.00 |
$1,037 |
| MAXYGEN |
$8.29 |
65% |
-16% |
$297 |
$190 |
$0 |
$107 |
$0.4 |
-$40 |
4.8 |
Dec-99 |
0.5 |
$16.00 |
$465 |
| RIGEL PHARMACEUTICALS |
$23.77 |
82% |
-6% |
$574 |
$136 |
$2 |
$440 |
$3.5 |
-$49 |
2.8 |
Nov-00 |
3.4 |
$7.00 |
$230 |
| SANGAMO BIOSCIENCES |
$4.39 |
68% |
-10% |
$112 |
$23 |
$0 |
$88 |
$1.6 |
-$14 |
1.7 |
Apr-00 |
0.3 |
$15.00 |
$312 |
| ZYMOGENETICS |
$16.50 |
67% |
-5% |
$957 |
$390 |
$66 |
$634 |
$1.8 |
-$95 |
4.1 |
Feb-01 |
1.4 |
$12.00 |
$547 |
| Genomic Targets Average |
|
67% |
-2% |
$356 |
$173 |
|
$230 |
$0.9 |
-$45 |
3.7 |
|
0.6 |
|
|
| Genomic Targets Median |
|
67% |
-8% |
$275 |
$143 |
|
$197 |
$0.6 |
-$49 |
3.3 |
|
0.5 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| ALEXION PHARMACEUTICALS |
$27.65 |
92% |
54% |
$777 |
$265 |
$150 |
$663 |
$3.5 |
-$130 |
2.0 |
Feb-96 |
3.4 |
$8.25 |
$62 |
| ATHEROGENICS |
$16.03 |
42% |
-51% |
$605 |
$200 |
$300 |
$706 |
$7.3 |
-$89 |
2.2 |
Aug-00 |
2.0 |
$8.00 |
$184 |
| CONNETICS CORP. |
$16.91 |
56% |
-37% |
$591 |
$267 |
$290 |
$615 |
$2.9 |
na |
na |
Feb-96 |
1.5 |
$11.00 |
$81 |
| CORTECH |
$2.85 |
81% |
1% |
$10 |
$0 |
$0 |
$10 |
$10.2 |
-$20 |
0.0 |
Nov-92 |
0.1 |
$40.00 |
$116 |
| CYPRESS BIOSCIENCE |
$5.41 |
37% |
-54% |
$171 |
$107 |
$0 |
$64 |
$4.3 |
-$20 |
5.5 |
Dec-83 |
0.1 |
$80.00 |
$33 |
| ICOS CORP. |
$27.62 |
93% |
14% |
$1,769 |
$144 |
$279 |
$1,904 |
$2.8 |
-$90 |
1.6 |
Jun-91 |
3.5 |
$8.00 |
$172 |
| INKINE PHARMACEUTICAL CO. |
$3.65 |
60% |
-28% |
$181 |
$13 |
$0 |
$168 |
$2.9 |
-$2 |
5.4 |
na |
na |
na |
na |
| LA JOLLA PHARMACEUTICAL |
$0.76 |
20% |
-75% |
$56 |
$16 |
$1 |
$41 |
$0.3 |
-$25 |
0.7 |
Jun-94 |
0.2 |
$5.00 |
$43 |
| PROTEIN DESIGN LABS |
$28.00 |
91% |
43% |
$2,999 |
$195 |
$508 |
$3,312 |
$6.0 |
-$14 |
14.3 |
Jan-92 |
3.7 |
$7.50 |
$191 |
| TANOX |
$14.65 |
78% |
-13% |
$657 |
$160 |
$5 |
$502 |
$4.3 |
-$22 |
7.4 |
Apr-00 |
0.5 |
$28.50 |
$1,193 |
| Autoimmune Average |
|
65% |
-15% |
$782 |
$137 |
|
$798 |
$4.4 |
-$46 |
4.3 |
|
1.7 |
|
|
| Autoimmune Median |
|
69% |
-21% |
$598 |
$152 |
|
$558 |
$3.9 |
-$22 |
2.2 |
|
1.5 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| ALLOS THERAPEUTICS |
$2.44 |
81% |
13% |
$134 |
$49 |
$0 |
$85 |
$1.4 |
-$20 |
2.5 |
Mar-00 |
0.1 |
$18.00 |
$604 |
| ANTIGENICS |
$5.42 |
48% |
-10% |
$247 |
$81 |
$57 |
$223 |
$1.0 |
-$84 |
1.0 |
Feb-00 |
0.3 |
$18.00 |
$429 |
| APHTON CORP. |
$0.63 |
16% |
-82% |
$38 |
$16 |
$13 |
$35 |
$0.7 |
-$51 |
0.3 |
na |
na |
na |
na |
| ARIAD PHARMACEUTICALS |
$7.43 |
85% |
11% |
$394 |
$98 |
$9 |
$304 |
$5.8 |
-$56 |
1.7 |
May-94 |
0.9 |
$8.00 |
$124 |
| AVI BIOPHARMA |
$2.64 |
62% |
29% |
$117 |
$22 |
$0 |
$94 |
$0.9 |
-$20 |
1.1 |
Jun-97 |
0.3 |
$9.00 |
$103 |
| BIOMIRA |
$1.38 |
33% |
-4% |
$109 |
$21 |
$0 |
$88 |
$0.6 |
-$16 |
1.3 |
Jun-87 |
0.3 |
$4.40 |
$43 |
| BOSTON LIFE SCIENCES |
$2.11 |
53% |
-10% |
$22 |
$1 |
$0 |
$21 |
$1.8 |
-$10 |
0.1 |
na |
na |
na |
na |
| CANCERVAX |
$3.44 |
30% |
-58% |
$96 |
$60 |
$15 |
$50 |
$0.3 |
-$29 |
2.1 |
Oct-03 |
0.3 |
$12.00 |
$308 |
| CELGENE CORP. |
$54.32 |
92% |
-7% |
$9,120 |
$821 |
$400 |
$8,699 |
$12.8 |
na |
na |
Jul-87 |
14.8 |
$3.66 |
$55 |
| CELL THERAPEUTICS |
$2.86 |
26% |
-58% |
$187 |
$12 |
$191 |
$366 |
$1.0 |
-$145 |
0.1 |
Mar-97 |
0.3 |
$10.00 |
$166 |
| CYTOGEN CORP. |
$4.04 |
26% |
-62% |
$69 |
$14 |
$0 |
$56 |
$0.9 |
-$31 |
0.4 |
Jun-86 |
0.3 |
$13.00 |
$148 |
| CYTOKINETICS |
$8.14 |
59% |
-37% |
$233 |
$81 |
$9 |
$161 |
$1.0 |
-$42 |
1.9 |
Apr-04 |
0.6 |
$13.00 |
$372 |
| DENDREON CORP. |
$6.71 |
50% |
-20% |
$398 |
$113 |
$5 |
$290 |
$2.0 |
-$70 |
1.6 |
Jun-00 |
0.7 |
$10.00 |
$210 |
| DUSA PHARMACEUTICALS |
$10.60 |
65% |
-8% |
$179 |
$35 |
$0 |
$144 |
$2.9 |
-$19 |
1.8 |
Jan-92 |
1.8 |
$6.00 |
$30 |
| ENTREMED |
$2.39 |
50% |
38% |
$119 |
$33 |
$0 |
$86 |
$1.9 |
-$17 |
1.9 |
Jun-96 |
0.2 |
$15.00 |
$182 |
| EXEGENICS |
$0.40 |
59% |
-42% |
$0 |
$8 |
$0 |
($8) |
($1.0) |
-$2 |
4.4 |
na |
na |
na |
na |
| FAVRILLE |
$4.55 |
61% |
na |
$92 |
$43 |
$7 |
$57 |
$0.5 |
-$38 |
1.1 |
2/2005 |
0.7 |
$7.00 |
$139 |
| GENAERA CORP. |
$1.92 |
44% |
-51% |
$110 |
$16 |
$0 |
$94 |
$4.1 |
-$23 |
0.7 |
Dec-91 |
0.2 |
$9.00 |
$62 |
| GENITOPE |
$6.94 |
39% |
-30% |
$196 |
$94 |
$0 |
$102 |
$1.1 |
-$33 |
2.9 |
Oct-03 |
0.8 |
$9.00 |
$145 |
| GENTA |
$1.50 |
50% |
-44% |
$143 |
$23 |
$0 |
$120 |
$0.8 |
na |
na |
Dec-91 |
0.0 |
$100.00 |
$123 |
| GERON CORP. |
$10.27 |
84% |
71% |
$571 |
$181 |
$2 |
$392 |
$7.4 |
-$12 |
14.6 |
Jul-96 |
1.3 |
$8.00 |
$77 |
| GTX |
$9.31 |
62% |
-20% |
$230 |
$40 |
$0 |
$190 |
$4.5 |
-$40 |
1.0 |
Feb-04 |
0.6 |
$14.50 |
$358 |
| IMCLONE SYSTEMS |
$31.45 |
56% |
-40% |
$2,634 |
$875 |
$600 |
$2,360 |
$5.6 |
na |
na |
Nov-91 |
4.5 |
$7.00 |
$107 |
| IMMUNOGEN |
$7.34 |
78% |
45% |
$301 |
$89 |
$0 |
$212 |
$1.8 |
-$11 |
8.3 |
Nov-89 |
0.7 |
$10.00 |
$60 |
| IMMUNOMEDICS |
$2.05 |
51% |
-21% |
$111 |
$22 |
$38 |
$127 |
$1.2 |
-$40 |
0.5 |
Oct-83 |
1.6 |
$1.25 |
$25 |
| MAXIM PHARMACEUTICALS |
$1.34 |
36% |
-50% |
$38 |
($6) |
$2 |
$46 |
$0.5 |
-$44 |
na |
Jul-96 |
0.2 |
$7.50 |
$50 |
| MEDAREX |
$9.52 |
82% |
29% |
$1,057 |
$363 |
$297 |
$991 |
$2.3 |
-$123 |
2.9 |
Jun-91 |
3.2 |
$3.00 |
$31 |
| NEOPHARM |
$12.40 |
80% |
45% |
$293 |
$41 |
$0 |
$251 |
$2.4 |
-$31 |
1.3 |
Jan-96 |
3.9 |
$3.18 |
$28 |
| NEORX CORP. |
$0.92 |
33% |
-46% |
$31 |
$3 |
$4 |
$32 |
$0.8 |
-$36 |
0.1 |
Aug-88 |
0.0 |
$28.00 |
$102 |
| ONYX PHARMACEUTICALS |
$24.97 |
56% |
-42% |
$883 |
$163 |
$0 |
$720 |
$45.0 |
-$72 |
2.3 |
May-96 |
2.1 |
$12.00 |
$105 |
| OSI PHARMACEUTICALS |
$29.24 |
39% |
-52% |
$1,503 |
$552 |
$150 |
$1,101 |
$2.3 |
-$98 |
5.6 |
Apr-86 |
4.9 |
$6.00 |
$53 |
| OXIGENE |
$5.27 |
81% |
-14% |
$106 |
$36 |
$0 |
$70 |
$6.3 |
-$12 |
2.9 |
Oct-93 |
0.9 |
$6.00 |
$28 |
| PHARMION |
$21.81 |
41% |
-58% |
$694 |
$237 |
$0 |
$457 |
$7.7 |
na |
na |
Nov-03 |
1.6 |
$14.00 |
$358 |
| PRAECIS PHARMACEUTICALS |
$0.47 |
19% |
-79% |
$25 |
$15 |
$32 |
$41 |
$0.2 |
-$170 |
0.1 |
Apr-00 |
0.0 |
$10.00 |
$400 |
| PROGENICS PHARMACEUTICALS |
$23.71 |
95% |
62% |
$505 |
$117 |
$0 |
$388 |
$3.4 |
-$51 |
2.3 |
Nov-97 |
3.0 |
$8.00 |
$70 |
| QLT |
$7.67 |
42% |
-54% |
$710 |
$456 |
$173 |
$427 |
$1.3 |
na |
na |
Sep-86 |
7.1 |
$1.08 |
$22 |
| SCICLONE PHARMACEUTICALS |
$5.64 |
69% |
58% |
$258 |
$49 |
$6 |
$215 |
$2.0 |
-$6 |
8.2 |
Mar-92 |
0.8 |
$7.45 |
$63 |
| SEATTLE GENETICS |
$5.25 |
67% |
-20% |
$222 |
$36 |
$0 |
$186 |
$1.7 |
-$34 |
1.1 |
Mar-01 |
0.8 |
$7.00 |
$207 |
| SPECTRUM PHARMACEUTICALS |
$4.96 |
66% |
-21% |
$76 |
$29 |
$0 |
$47 |
$2.9 |
-$18 |
1.6 |
na |
na |
na |
na |
| SUPERGEN |
$6.30 |
79% |
2% |
$323 |
$53 |
$0 |
$270 |
$2.3 |
-$8 |
7.0 |
Mar-96 |
1.1 |
$6.00 |
$21 |
| TAPESTRY PHARMACEUTICALS |
$0.37 |
27% |
-64% |
$13 |
$18 |
$3 |
($2) |
($0.0) |
-$18 |
1.0 |
Apr-94 |
0.1 |
$5.00 |
$41 |
| THRESHOLD PHARMACEUTICALS |
$13.65 |
97% |
na |
$420 |
$46 |
$1 |
$375 |
$8.9 |
-$41 |
1.1 |
2/2005 |
2.0 |
$7.00 |
$204 |
| VERNALIS |
$2.43 |
62% |
-21% |
$12 |
$69 |
$116 |
$59 |
$0.7 |
-$64 |
1.1 |
May-96 |
0.3 |
$7.20 |
$178 |
| XCYTE THERAPIES |
$0.48 |
13% |
-85% |
$9 |
$28 |
$2 |
($17) |
($0.2) |
-$24 |
1.2 |
Mar-04 |
0.1 |
$8.00 |
$157 |
| XENOVA PLC |
$0.52 |
28% |
-68% |
$22 |
$26 |
$0 |
($4) |
($0.0) |
-$12 |
2.3 |
Jul-94 |
0.0 |
$16.00 |
$90 |
| Cancer Average |
|
55% |
-20% |
$512 |
$115 |
|
$444 |
$3.4 |
-$42 |
2.4 |
|
1.5 |
|
|
| Cancer Median |
|
56% |
-21% |
$179 |
$41 |
|
$127 |
$1.7 |
-$32 |
1.6 |
|
0.7 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| CARDIOVASCULAR BIOTHER. |
$8.80 |
58% |
na |
$1,078 |
$11 |
$0 |
$1,067 |
$266.8 |
-$10 |
1.1 |
2/2005 |
0.9 |
$10.00 |
$1,184 |
| CORGENTECH |
$2.36 |
12% |
-86% |
$66 |
$92 |
$0 |
($25) |
($0.4) |
-$23 |
4.0 |
Feb-04 |
0.1 |
$16.00 |
$448 |
| CV THERAPEUTICS |
$26.75 |
90% |
114% |
$1,191 |
$321 |
$330 |
$1,200 |
$4.6 |
-$206 |
1.6 |
Nov-96 |
3.3 |
$8.00 |
$48 |
| ENCYSIVE PHARMACEUTICALS |
$11.78 |
89% |
30% |
$686 |
$146 |
$130 |
$670 |
$7.3 |
-$77 |
1.9 |
Dec-93 |
1.7 |
$6.75 |
$88 |
| MEDICINES COMPANY |
$23.01 |
77% |
-5% |
$1,141 |
$148 |
$0 |
$994 |
$5.2 |
na |
na |
Sep-00 |
1.4 |
$16.00 |
$506 |
| MYOGEN |
$23.50 |
94% |
190% |
$843 |
$174 |
$1 |
$670 |
$11.7 |
-$86 |
2.0 |
Oct-03 |
1.7 |
$14.00 |
$358 |
| NITROMED |
$18.00 |
64% |
-24% |
$547 |
$100 |
$20 |
$467 |
$11.4 |
-$90 |
1.1 |
Nov-03 |
1.6 |
$11.00 |
$264 |
| NUVELO |
$9.60 |
85% |
-3% |
$404 |
$78 |
$14 |
$341 |
$5.4 |
-$68 |
1.1 |
Sep-97 |
0.7 |
$14.00 |
$175 |
| QUESTCOR PHARMACEUTICALS |
$0.54 |
64% |
20% |
$29 |
$6 |
$2 |
$25 |
$0.5 |
na |
na |
na |
na |
na |
na |
| Cardiovascular Average |
|
70% |
30% |
$665 |
$119 |
|
$601 |
$34.7 |
-$80 |
1.8 |
|
1.4 |
|
|
| Cardiovascular Median |
|
77% |
9% |
$686 |
$100 |
|
$670 |
$5.4 |
-$77 |
1.6 |
|
1.5 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| ACCELRYS |
$6.76 |
83% |
4% |
$177 |
$50 |
$4 |
$130 |
$0.2 |
-$15 |
3.4 |
Dec-95 |
0.4 |
$16.00 |
$158 |
| ALBANY MOLECULAR RESEARCH |
$12.18 |
71% |
27% |
$394 |
$160 |
$51 |
$285 |
$0.3 |
na |
na |
Feb-99 |
1.2 |
$10.00 |
$280 |
| ARGONAUT TECHNOLOGIES |
$0.31 |
28% |
-67% |
$6 |
$8 |
$0 |
($1) |
($0.0) |
-$9 |
0.9 |
Jul-00 |
0.0 |
$15.00 |
$253 |
| ARQULE |
$7.83 |
93% |
69% |
$275 |
$131 |
$0 |
$144 |
$0.6 |
-$10 |
13.7 |
Oct-96 |
0.7 |
$12.00 |
$114 |
| ARRAY BIOPHARMA |
$7.18 |
72% |
3% |
$276 |
$87 |
$10 |
$199 |
$0.8 |
-$26 |
3.4 |
Nov-01 |
1.0 |
$7.50 |
$168 |
| BIOCRYST PHARMACEUTICALS |
$9.78 |
94% |
92% |
$256 |
$28 |
$0 |
$228 |
$5.0 |
-$22 |
1.3 |
Mar-94 |
1.5 |
$6.50 |
$47 |
| DISCOVERY PARTNERS INTL. |
$3.22 |
59% |
-33% |
$84 |
$81 |
$0 |
$4 |
$0.0 |
-$6 |
14.4 |
Jul-00 |
0.2 |
$18.00 |
$428 |
| KOSAN BIOSCIENCES |
$7.27 |
74% |
26% |
$213 |
$49 |
$4 |
$168 |
$1.3 |
-$29 |
1.7 |
Oct-00 |
0.5 |
$14.00 |
$341 |
| SYMYX TECHNOLOGIES |
$26.12 |
81% |
11% |
$861 |
$149 |
$0 |
$712 |
$3.0 |
na |
na |
Nov-99 |
1.9 |
$14.00 |
$398 |
| VERTEX PHARMACEUTICALS |
$22.35 |
99% |
113% |
$2,138 |
$451 |
$335 |
$2,022 |
$2.8 |
na |
na |
Jul-91 |
5.0 |
$4.50 |
$85 |
| Chemistry Average |
|
75% |
24% |
$468 |
$119 |
|
$389 |
$1.4 |
-$17 |
5.5 |
|
1.2 |
|
|
| Chemistry Average |
|
78% |
19% |
$266 |
$84 |
|
$183 |
$0.7 |
-$15 |
3.4 |
|
0.8 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| ACADIA PHARMACEUTICALS |
$11.37 |
97% |
46% |
$267 |
$65 |
$2 |
$203 |
$2.0 |
-$24 |
2.7 |
May-04 |
1.6 |
$7.00 |
$164 |
| ADOLOR CORP. |
$10.68 |
63% |
-5% |
$417 |
$123 |
$0 |
$295 |
$2.3 |
-$55 |
2.2 |
Nov-00 |
0.7 |
$15.00 |
$407 |
| CEPHALON |
$46.42 |
89% |
-3% |
$2,695 |
$1,378 |
$2,085 |
$3,403 |
$2.1 |
na |
na |
Apr-91 |
2.6 |
$18.00 |
$155 |
| CORCEPT THERAPEUTICS |
$5.00 |
63% |
-36% |
$114 |
$30 |
$0 |
$84 |
$12.0 |
-$16 |
1.8 |
Apr-04 |
0.4 |
$12.00 |
$272 |
| DOV PHARMACEUTICAL |
$16.98 |
79% |
-1% |
$391 |
$100 |
$80 |
$371 |
$10.3 |
-$45 |
2.2 |
Apr-02 |
1.3 |
$13.00 |
$188 |
| GUILFORD PHARMACEUTICALS |
$3.65 |
64% |
-27% |
$170 |
$56 |
$72 |
$186 |
$0.7 |
-$106 |
0.5 |
Jun-94 |
0.7 |
$5.33 |
$30 |
| INDEVUS PHARMACEUTICALS |
$2.88 |
39% |
-59% |
$135 |
$101 |
$72 |
$106 |
$3.9 |
-$39 |
2.6 |
Mar-90 |
1.4 |
$2.00 |
$31 |
| MEMORY PHARMACEUTICALS |
$2.71 |
38% |
-65% |
$57 |
$18 |
$3 |
$42 |
$0.6 |
-$34 |
0.5 |
Apr-04 |
0.4 |
$7.00 |
$147 |
| NEUROBIOLOGICAL TECHNOLOGIES |
$3.81 |
75% |
9% |
$103 |
$1 |
$0 |
$102 |
$9.3 |
-$14 |
0.1 |
Feb-94 |
0.5 |
$8.00 |
$30 |
| NEUROCRINE BIOSCIENCES |
$49.19 |
93% |
4% |
$1,810 |
$243 |
$63 |
$1,630 |
$5.2 |
-$22 |
10.9 |
May-96 |
4.7 |
$10.50 |
$172 |
| NEW RIVER PHARMACEUTICALS |
$47.94 |
100% |
384% |
$863 |
$56 |
$0 |
$807 |
$36.7 |
-$26 |
2.2 |
Aug-04 |
6.0 |
$8.00 |
$142 |
| NYMOX PHARMACEUTICAL CORP. |
$2.16 |
62% |
5% |
$55 |
($1) |
$1 |
$57 |
$2.7 |
-$4 |
na |
na |
na |
na |
na |
| PAIN THERAPEUTICS |
$6.29 |
77% |
-13% |
$276 |
$71 |
$0 |
$204 |
$6.8 |
-$41 |
1.8 |
Jul-00 |
0.5 |
$12.00 |
$319 |
| PHARMOS CORP. |
$2.14 |
10% |
-85% |
$41 |
$49 |
$0 |
($8) |
($0.2) |
-$13 |
3.7 |
Jul-83 |
0.0 |
$100.00 |
$16 |
| RENOVIS |
$13.53 |
70% |
69% |
$336 |
$115 |
$4 |
$225 |
$3.1 |
-$40 |
2.9 |
Feb-04 |
1.1 |
$12.00 |
$298 |
| TITAN PHARMACEUTICALS |
$1.77 |
52% |
-26% |
$57 |
$20 |
$0 |
$38 |
$0.6 |
-$23 |
0.9 |
Jan-96 |
0.4 |
$5.00 |
$66 |
| CNS Average |
|
67% |
12% |
$487 |
$152 |
|
$484 |
$6.1 |
-$33 |
2.5 |
|
1.5 |
|
|
| CNS Median |
|
67% |
-4% |
$218 |
$61 |
|
$194 |
$2.9 |
-$26 |
2.2 |
|
0.7 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| ABGENIX |
$12.68 |
98% |
29% |
$1,139 |
$303 |
$464 |
$1,300 |
$3.2 |
-$336 |
0.9 |
Jul-98 |
6.3 |
$2.00 |
$86 |
| ACUSPHERE |
$5.44 |
78% |
-13% |
$97 |
$64 |
$17 |
$50 |
$0.9 |
-$61 |
1.0 |
Oct-03 |
0.4 |
$14.00 |
$200 |
| AEROGEN |
$0.74 |
28% |
-66% |
$5 |
$14 |
$0 |
($9) |
($0.1) |
-$1 |
11.8 |
Nov-00 |
0.1 |
$12.00 |
$233 |
| ALKERMES |
$16.80 |
85% |
46% |
$1,521 |
$327 |
$278 |
$1,472 |
$3.4 |
-$55 |
6.0 |
Jul-91 |
3.4 |
$5.00 |
$70 |
| ANDRX CORP. |
$15.43 |
63% |
-31% |
$1,131 |
$398 |
$0 |
$733 |
$0.3 |
na |
na |
Jun-96 |
5.1 |
$3.00 |
$155 |
| ARADIGM CORP. |
$1.07 |
50% |
-16% |
$78 |
$38 |
$0 |
$40 |
$0.2 |
-$34 |
1.1 |
Jun-96 |
0.1 |
$11.00 |
$114 |
| BIODELIVERY SCIENCES INTL. |
$1.80 |
42% |
-35% |
$13 |
($1) |
$3 |
$17 |
$0.9 |
-$11 |
na |
na |
na |
na |
na |
| DEPOMED |
$6.48 |
95% |
24% |
$258 |
$11 |
$0 |
$247 |
$3.3 |
-$27 |
0.4 |
Nov-97 |
1.1 |
$6.10 |
$33 |
| DOR BIOPHARMA |
$0.33 |
41% |
-40% |
$17 |
$3 |
$0 |
$14 |
$3.5 |
-$2 |
1.4 |
na |
na |
na |
na |
| DURECT CORP. |
$6.85 |
92% |
389% |
$358 |
$47 |
$69 |
$381 |
$3.5 |
-$14 |
3.2 |
Sep-00 |
0.6 |
$12.00 |
$557 |
| EMISPHERE TECHNOLOGIES |
$4.50 |
75% |
47% |
$105 |
$6 |
$10 |
$109 |
$0.9 |
-$23 |
0.3 |
Feb-89 |
0.9 |
$5.00 |
$15 |
| ENZON PHARMACEUTICALS |
$6.60 |
39% |
-59% |
$292 |
$157 |
$400 |
$535 |
$1.7 |
-$18 |
8.5 |
Feb-84 |
4.4 |
$1.50 |
$12 |
| FLAMEL TECHNOLOGIES SA |
$18.70 |
85% |
27% |
$425 |
$112 |
$3 |
$316 |
$2.1 |
-$8 |
14.7 |
na |
na |
na |
na |
| GENEREX BIOTECHNOLOGY CORP. |
$0.67 |
61% |
-38% |
$27 |
($4) |
$5 |
$35 |
$1.3 |
-$19 |
na |
na |
na |
na |
na |
| INOVIO BIOMEDICAL CORP. |
$2.72 |
54% |
-8% |
$46 |
$6 |
$0 |
$41 |
$2.0 |
-$8 |
0.7 |
na |
na |
na |
na |
| KOS PHARMACEUTICALS |
$66.93 |
85% |
88% |
$3,067 |
$342 |
$0 |
$2,726 |
$3.0 |
na |
na |
Mar-97 |
4.5 |
$15.00 |
$233 |
| MEDICIS PHARMACEUTICAL CORP. |
$32.56 |
79% |
-17% |
$1,771 |
$655 |
$481 |
$1,596 |
$5.1 |
na |
na |
na |
na |
na |
na |
| NASTECH PHARMACEUTICAL CO. |
$14.14 |
85% |
-1% |
$266 |
$68 |
$4 |
$202 |
$2.5 |
-$33 |
2.1 |
na |
na |
na |
na |
| NEKTAR THERAPEUTICS |
$16.95 |
79% |
17% |
$1,447 |
$361 |
$195 |
$1,280 |
$1.9 |
-$108 |
3.4 |
May-94 |
4.5 |
$3.75 |
$65 |
| NOVAVAX |
$1.75 |
43% |
-44% |
$76 |
$0 |
$37 |
$113 |
$1.0 |
-$23 |
0.0 |
na |
na |
na |
na |
| NOVEN PHARMACEUTICALS |
$14.00 |
57% |
-33% |
$330 |
$98 |
$0 |
$232 |
$0.8 |
na |
na |
May-88 |
25.5 |
$0.55 |
$5 |
| SEPRACOR |
$58.99 |
89% |
21% |
$6,216 |
$791 |
$1,164 |
$6,589 |
$6.7 |
-$30 |
26.7 |
Sep-91 |
11.8 |
$5.00 |
$168 |
| XENOPORT |
$16.50 |
92% |
na |
$326 |
$77 |
$2 |
$250 |
$2.5 |
-$47 |
1.6 |
7/2004 |
2.4 |
$7.00 |
$104 |
| Delivery Average |
|
69% |
13% |
$827 |
$168 |
|
$794 |
$2.2 |
-$45 |
4.9 |
|
4.7 |
|
|
| Delivery Median |
|
78% |
-11% |
$292 |
$68 |
|
$247 |
$2.0 |
-$23 |
1.6 |
|
3.4 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| ADEZA BIOMEDICAL |
$17.41 |
83% |
na |
$293 |
$85 |
$0 |
$208 |
$2.5 |
na |
na |
12/2004 |
1.1 |
$16.00 |
$259 |
| ADVANCED MAGNETICS |
$9.71 |
40% |
-30% |
$96 |
$24 |
$0 |
$72 |
$3.3 |
-$13 |
1.8 |
na |
na |
na |
na |
| BIOSITE |
$61.86 |
92% |
26% |
$1,067 |
$145 |
$20 |
$943 |
$1.2 |
na |
na |
Feb-97 |
5.2 |
$12.00 |
$149 |
| CHOLESTECH CORP. |
$10.08 |
74% |
49% |
$148 |
$30 |
$0 |
$118 |
$0.6 |
na |
na |
Jun-92 |
2.0 |
$5.00 |
$32 |
| DIAGNOSTIC PRODUCTS CORP. |
$52.73 |
91% |
29% |
$1,548 |
$111 |
$3 |
$1,440 |
$0.6 |
na |
na |
Jun-82 |
13.2 |
$4.00 |
$43 |
| DIGENE CORP. |
$28.50 |
89% |
10% |
$573 |
$47 |
$1 |
$527 |
$1.8 |
-$15 |
3.1 |
May-96 |
2.5 |
$11.50 |
$128 |
| ENZO BIOCHEM |
$15.36 |
74% |
2% |
$494 |
$82 |
$0 |
$412 |
$1.9 |
-$6 |
13.6 |
Jun-80 |
17.7 |
$0.87 |
$8 |
| EPIX PHARMACEUTICALS |
$7.70 |
39% |
-60% |
$179 |
$145 |
$115 |
$149 |
$1.7 |
-$28 |
5.1 |
Feb-97 |
1.1 |
$7.00 |
$59 |
| EXACT SCIENCES CORP. |
$1.82 |
38% |
-44% |
$48 |
$38 |
$0 |
$9 |
$0.1 |
-$16 |
2.4 |
Jan-01 |
0.1 |
$14.00 |
$261 |
| GEN-PROBE |
$49.45 |
93% |
24% |
$2,507 |
$242 |
$0 |
$2,265 |
$3.1 |
na |
na |
Sep-87 |
7.1 |
$7.00 |
$103 |
| IDEXX LABORATORIES |
$66.88 |
98% |
32% |
$2,177 |
$172 |
$16 |
$2,021 |
$0.8 |
na |
na |
Jun-91 |
17.8 |
$3.75 |
$76 |
| IMMUCOR |
$27.44 |
76% |
66% |
$1,247 |
$31 |
$9 |
$1,225 |
$3.3 |
na |
na |
na |
na |
na |
na |
| IMMUNICON |
$3.93 |
39% |
-61% |
$108 |
$51 |
$6 |
$63 |
$0.6 |
-$28 |
1.8 |
Apr-04 |
0.5 |
$8.00 |
$220 |
| LUMINEX CORP. |
$10.04 |
90% |
41% |
$317 |
$29 |
$0 |
$288 |
$2.2 |
-$2 |
18.0 |
Mar-00 |
0.6 |
$17.00 |
$450 |
| MARTEK BIOSCIENCES CORP. |
$35.13 |
50% |
-28% |
$1,114 |
$57 |
$74 |
$1,131 |
$2.9 |
-$0 |
141.8 |
Nov-93 |
5.0 |
$7.00 |
$54 |
| MATRITECH |
$0.63 |
43% |
-46% |
$29 |
$5 |
$1 |
$25 |
$0.4 |
-$6 |
0.8 |
Jul-92 |
0.1 |
$5.00 |
$22 |
| MERIDIAN BIOSCIENCE |
$20.70 |
99% |
139% |
$497 |
$10 |
$10 |
$497 |
$2.1 |
na |
na |
na |
na |
na |
na |
| ORASURE TECHNOLOGIES |
$9.45 |
80% |
50% |
$428 |
$74 |
$2 |
$356 |
$2.1 |
na |
na |
na |
na |
na |
na |
| QUIDEL CORP. |
$9.46 |
97% |
109% |
$311 |
$27 |
$9 |
$293 |
$1.0 |
-$7 |
3.8 |
Aug-81 |
0.9 |
$10.00 |
$19 |
| SONUS PHARMACEUTICALS |
$4.25 |
84% |
15% |
$91 |
$7 |
$0 |
$84 |
$2.0 |
-$16 |
0.5 |
Oct-95 |
0.6 |
$7.00 |
$60 |
| STRATAGENE |
$9.01 |
86% |
25% |
$200 |
$13 |
$4 |
$191 |
$1.3 |
na |
na |
na |
na |
na |
na |
| TRINITY BIOTECH PLC |
$7.40 |
58% |
147% |
$103 |
$28 |
$23 |
$98 |
$0.2 |
na |
na |
na |
na |
na |
na |
| XENOGEN |
$3.07 |
42% |
-50% |
$46 |
$10 |
$7 |
$43 |
$0.3 |
-$15 |
0.7 |
Jul-04 |
0.4 |
$7.00 |
$103 |
| Diagnostic/imag. Average |
|
72% |
20% |
$592 |
$64 |
|
$542 |
$1.6 |
-$13 |
16.1 |
|
4.5 |
|
|
| Diagnostic/imag. Median |
|
80% |
25% |
$311 |
$38 |
|
$288 |
$1.7 |
-$14 |
2.8 |
|
1.1 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| AASTROM BIOSCIENCES |
$2.35 |
54% |
153% |
$241 |
$29 |
$0 |
$211 |
$4.8 |
-$14 |
2.2 |
Feb-97 |
0.3 |
$7.00 |
$88 |
| AVIGEN |
$2.78 |
73% |
-25% |
$58 |
$49 |
$8 |
$17 |
$0.2 |
-$39 |
1.2 |
May-96 |
0.3 |
$8.00 |
$58 |
| CELL GENESYS |
$5.48 |
58% |
-39% |
$249 |
$152 |
$196 |
$293 |
$1.1 |
-$110 |
1.4 |
Jan-93 |
0.5 |
$11.00 |
$120 |
| CORAUTUS GENETICS |
$4.45 |
64% |
-18% |
$78 |
$27 |
$17 |
$67 |
$2.2 |
-$22 |
1.2 |
na |
na |
na |
na |
| GENVEC |
$2.05 |
67% |
-21% |
$114 |
$24 |
$4 |
$95 |
$1.1 |
-$12 |
2.0 |
Dec-00 |
0.2 |
$9.50 |
$186 |
| INTROGEN THERAPEUTICS |
$5.22 |
53% |
-17% |
$174 |
$20 |
$9 |
$162 |
$2.3 |
-$28 |
0.7 |
Oct-00 |
0.7 |
$8.00 |
$167 |
| SIRNA THERAPEUTICS |
$4.40 |
79% |
44% |
$262 |
$13 |
$0 |
$248 |
$3.5 |
-$24 |
0.6 |
Apr-96 |
0.4 |
$10.00 |
$59 |
| STEMCELLS |
$5.52 |
82% |
258% |
$353 |
$33 |
$2 |
$322 |
$11.5 |
-$16 |
2.1 |
Mar-92 |
0.5 |
$11.00 |
$82 |
| TARGETED GENETICS CORP. |
$0.68 |
34% |
-50% |
$58 |
$21 |
$11 |
$48 |
$0.5 |
-$21 |
1.0 |
May-94 |
0.1 |
$6.00 |
$54 |
| VALENTIS |
$2.38 |
61% |
-11% |
$35 |
$10 |
$0 |
$25 |
$1.3 |
-$10 |
1.0 |
Sep-97 |
0.2 |
$12.00 |
$161 |
| VIACELL |
$5.80 |
40% |
na |
$220 |
$65 |
$3 |
$158 |
$0.9 |
-$12 |
5.2 |
1/2005 |
0.8 |
$7.00 |
$259 |
| VICAL |
$4.92 |
84% |
3% |
$116 |
$54 |
$9 |
$71 |
$0.4 |
-$20 |
2.7 |
Mar-93 |
1.0 |
$5.00 |
$52 |
| Gene/Cell therapy Average |
|
62% |
25% |
$163 |
$41 |
|
$143 |
$2.5 |
-$27 |
1.8 |
|
0.5 |
|
|
| Gene/Cell therapy Median |
|
62% |
-17% |
$145 |
$28 |
|
$126 |
$1.2 |
-$21 |
1.3 |
|
0.4 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| ADVANCED LIFE SCIENCES |
$4.97 |
86% |
na |
$89 |
$26 |
$6 |
$68 |
$3.4 |
-$27 |
0.9 |
8/2005 |
1.0 |
$5.00 |
$85 |
| ADVANCIS |
$1.41 |
16% |
-83% |
$42 |
$32 |
$2 |
$12 |
$0.2 |
-$37 |
0.9 |
Oct-03 |
0.1 |
$10.00 |
$224 |
| ANADYS PHARMACEUTICALS |
$10.67 |
75% |
101% |
$302 |
$15 |
$2 |
$289 |
$3.5 |
-$28 |
0.5 |
Mar-04 |
1.5 |
$7.00 |
$198 |
| AVANT IMMUNOTHERAPEUTICS |
$1.30 |
53% |
-24% |
$96 |
$23 |
$0 |
$73 |
$1.2 |
-$19 |
1.2 |
May-86 |
0.3 |
$4.00 |
$38 |
| CUBIST PHARMACEUTICALS |
$21.54 |
100% |
118% |
$1,154 |
$94 |
$165 |
$1,225 |
$4.2 |
-$31 |
3.1 |
Oct-96 |
3.6 |
$6.00 |
$55 |
| DYNAVAX TECHNOLOGIES |
$6.70 |
76% |
-12% |
$166 |
$52 |
$0 |
$114 |
$2.6 |
-$34 |
1.5 |
Feb-04 |
0.9 |
$7.50 |
$186 |
| GENELABS TECHNOLOGIES |
$0.64 |
24% |
-75% |
$57 |
$16 |
$0 |
$41 |
$0.6 |
-$12 |
1.4 |
Jun-91 |
0.1 |
$9.13 |
$160 |
| IDENIX PHARMACEUTICALS |
$25.10 |
89% |
57% |
$1,211 |
$106 |
$3 |
$1,107 |
$7.7 |
-$54 |
2.0 |
Jul-04 |
1.8 |
$14.00 |
$684 |
| IMMUNE RESPONSE CORP. |
$0.46 |
26% |
-62% |
$23 |
($4) |
$5 |
$32 |
$0.7 |
-$20 |
na |
May-90 |
0.0 |
$28.00 |
$77 |
| INHIBITEX |
$10.18 |
80% |
51% |
$256 |
$58 |
$5 |
$203 |
$3.3 |
-$40 |
1.4 |
Jun-04 |
1.5 |
$7.00 |
$176 |
| INTERMUNE |
$16.55 |
91% |
40% |
$539 |
$121 |
$170 |
$588 |
$2.3 |
-$95 |
1.3 |
Mar-00 |
0.8 |
$20.00 |
$433 |
| MONOGRAM BIOSCIENCES |
$2.35 |
80% |
18% |
$297 |
$77 |
$0 |
$220 |
$1.2 |
na |
na |
May-00 |
0.3 |
$7.00 |
$137 |
| NABI BIOPHARMACEUTICALS |
$13.10 |
82% |
-2% |
$775 |
$157 |
$124 |
$742 |
$1.1 |
-$84 |
1.9 |
na |
na |
na |
na |
| SIGA TECHNOLOGIES |
$1.06 |
59% |
-20% |
$26 |
($1) |
$0 |
$27 |
$1.6 |
-$6 |
na |
Sep-97 |
0.2 |
$5.00 |
$32 |
| TRIMERIS |
$15.34 |
95% |
2% |
$337 |
$41 |
$0 |
$296 |
$3.0 |
-$12 |
3.3 |
Oct-97 |
1.3 |
$12.00 |
$120 |
| VAXGEN |
$14.50 |
73% |
9% |
$0 |
$0 |
$0 |
$0 |
$0.0 |
na |
na |
Jul-99 |
1.1 |
$13.00 |
$146 |
| VIROPHARMA |
$20.80 |
97% |
978% |
$579 |
$46 |
$101 |
$635 |
$7.2 |
na |
na |
Nov-96 |
3.0 |
$7.00 |
$65 |
| XOMA LTD |
$1.76 |
58% |
-24% |
$152 |
$49 |
$60 |
$163 |
$0.7 |
-$34 |
1.4 |
Jun-86 |
0.1 |
$16.00 |
$140 |
| Infection Average |
|
70% |
63% |
$339 |
$50 |
|
$324 |
$2.5 |
-$36 |
1.6 |
|
1.0 |
|
|
| Infection Median |
|
78% |
2% |
$211 |
$43 |
|
$183 |
$1.9 |
-$31 |
1.4 |
|
0.9 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| AMYLIN PHARMACEUTICALS |
$34.79 |
98% |
70% |
$3,635 |
$390 |
$375 |
$3,620 |
$16.1 |
-$106 |
3.7 |
Jan-92 |
2.5 |
$14.00 |
$240 |
| BIOMARIN PHARMACEUTICAL |
$8.73 |
92% |
68% |
$643 |
$12 |
$228 |
$860 |
$3.2 |
-$85 |
0.1 |
Aug-99 |
0.7 |
$13.00 |
$449 |
| INSMED |
$1.34 |
54% |
-20% |
$60 |
$21 |
$20 |
$60 |
$3.0 |
-$34 |
0.6 |
na |
na |
na |
na |
| KERYX BIOPHARMACEUTICALS |
$15.76 |
89% |
41% |
$590 |
$27 |
$0 |
$563 |
$23.5 |
-$24 |
1.1 |
Jul-00 |
1.6 |
$10.00 |
$194 |
| MANNKIND |
$13.69 |
69% |
-32% |
$687 |
$18 |
$0 |
$669 |
$3.0 |
-$109 |
0.2 |
Jul-04 |
1.0 |
$14.00 |
$446 |
| METABASIS THERAPEUTICS |
$5.83 |
72% |
0% |
$106 |
$29 |
$2 |
$80 |
$1.0 |
-$23 |
1.3 |
Jun-04 |
0.8 |
$7.00 |
$128 |
| NPS PHARMACEUTICALS |
$10.11 |
44% |
-54% |
$393 |
$209 |
$367 |
$551 |
$2.0 |
-$169 |
1.2 |
May-94 |
1.8 |
$5.50 |
$40 |
| SAVIENT PHARMACEUTICALS |
$4.09 |
85% |
78% |
$249 |
$101 |
$4 |
$152 |
$0.3 |
-$16 |
6.5 |
Sep-83 |
0.3 |
$13.00 |
$68 |
| TERCICA |
$11.28 |
88% |
25% |
$356 |
$73 |
$0 |
$284 |
$6.9 |
-$50 |
1.5 |
Mar-04 |
1.3 |
$9.00 |
$284 |
| VIVUS |
$3.59 |
56% |
-20% |
$160 |
$32 |
$4 |
$132 |
$1.1 |
-$35 |
0.9 |
Apr-94 |
0.5 |
$7.00 |
$164 |
| ZONAGEN |
$5.75 |
98% |
59% |
$58 |
$20 |
$0 |
$38 |
$9.5 |
-$6 |
3.1 |
Mar-93 |
1.0 |
$5.50 |
$19 |
| Metabolic Average |
|
77% |
20% |
$631 |
$85 |
|
$637 |
$6.3 |
-$60 |
1.8 |
|
1.2 |
|
|
| Metabolic Median |
|
85% |
25% |
$356 |
$29 |
|
$284 |
$3.0 |
-$35 |
1.2 |
|
1.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| ALNYLAM PHARMACEUTICALS |
$11.30 |
74% |
96% |
$240 |
$22 |
$8 |
$226 |
$3.8 |
-$44 |
0.5 |
May-04 |
1.9 |
$6.00 |
$127 |
| ASPREVA PHARMACEUTICALS |
$14.26 |
83% |
na |
$485 |
$103 |
$1 |
$383 |
$7.2 |
na |
na |
3/2005 |
1.3 |
$11.00 |
$362 |
| AUXILIUM PHARMACEUTICALS |
$4.98 |
49% |
-42% |
$145 |
$61 |
$1 |
$85 |
$0.6 |
-$34 |
1.8 |
Jul-04 |
0.7 |
$7.50 |
$160 |
| BARRIER THERAPEUTICS |
$8.39 |
37% |
-31% |
$202 |
$91 |
$1 |
$112 |
$2.7 |
-$43 |
2.1 |
Apr-04 |
0.6 |
$15.00 |
$361 |
| COLEY PHARMACEUTICAL |
$18.20 |
94% |
na |
$470 |
$46 |
$4 |
$428 |
$3.3 |
-$32 |
1.5 |
8/2005 |
1.1 |
$16.00 |
$399 |
| COTHERIX |
$13.95 |
90% |
na |
$335 |
$50 |
$0 |
$284 |
$7.3 |
-$25 |
2.0 |
10/2004 |
2.3 |
$6.00 |
$116 |
| CRITICAL THERAPEUTICS |
$9.42 |
97% |
126% |
$321 |
$102 |
$2 |
$221 |
$2.2 |
-$37 |
2.7 |
May-04 |
1.3 |
$7.00 |
$238 |
| EYETECH PHARMACEUTICALS |
$17.96 |
37% |
-47% |
$808 |
$263 |
$2 |
$547 |
$3.4 |
-$28 |
9.3 |
Jan-04 |
0.9 |
$21.00 |
$945 |
| ICAGEN |
$6.75 |
68% |
na |
$147 |
$54 |
$1 |
$93 |
$1.4 |
-$20 |
2.8 |
2/2005 |
0.8 |
$8.00 |
$176 |
| MOMENTA PHARMACEUTICALS |
$27.25 |
79% |
231% |
$827 |
$44 |
$3 |
$786 |
$21.8 |
-$18 |
2.4 |
Jun-04 |
4.2 |
$6.50 |
$197 |
| SANTARUS |
$6.21 |
58% |
-32% |
$228 |
$56 |
$0 |
$172 |
$2.5 |
-$78 |
0.7 |
Mar-04 |
0.7 |
$9.00 |
$331 |
| Other Average |
|
70% |
43% |
$382 |
$81 |
|
$303 |
$5.1 |
-$36 |
2.6 |
|
1.4 |
|
|
| Other Median |
|
74% |
-31% |
$321 |
$56 |
|
$226 |
$3.3 |
-$33 |
2.0 |
|
1.1 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| AMGEN |
$79.67 |
92% |
40% |
$98,297 |
$6,363 |
$3,947 |
$95,881 |
$7.4 |
na |
na |
Jun-83 |
227.6 |
$0.35 |
$175 |
| BIOGEN IDEC |
$39.48 |
56% |
-35% |
$13,358 |
$1,192 |
$42 |
$12,208 |
$3.3 |
na |
na |
Sep-91 |
15.8 |
$2.50 |
$131 |
| CHIRON CORP. |
$43.65 |
95% |
-1% |
$8,201 |
$758 |
$1,097 |
$8,539 |
$1.6 |
na |
na |
Aug-83 |
14.6 |
$3.00 |
$98 |
| GENENTECH |
$84.21 |
89% |
61% |
$89,623 |
$2,717 |
$485 |
$87,391 |
$14.0 |
na |
na |
Oct-80 |
58.1 |
$1.45 |
$246 |
| GENZYME CORP. |
$71.64 |
94% |
32% |
$18,388 |
$1,498 |
$1,189 |
$18,080 |
$3.2 |
na |
na |
Jun-86 |
28.7 |
$2.50 |
$70 |
| GILEAD SCIENCES |
$48.76 |
99% |
30% |
$22,231 |
$2,043 |
$0 |
$20,189 |
$14.2 |
na |
na |
Jan-92 |
13.0 |
$3.75 |
$210 |
| MEDIMMUNE |
$33.65 |
99% |
42% |
$8,289 |
$717 |
$506 |
$8,078 |
$4.9 |
-$177 |
4.1 |
May-91 |
21.9 |
$1.54 |
$114 |
| Revenue-driven Average |
|
89% |
24% |
$36,912 |
$2,184 |
|
$35,767 |
$6.9 |
na |
na |
|
54.2 |
|
|
| Revenue-driven Median |
|
94% |
32% |
$18,388 |
$1,498 |
|
$18,080 |
$4.9 |
na |
na |
|
21.9 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| DIVERSA CORP. |
$5.79 |
61% |
-31% |
$258 |
$70 |
$16 |
$204 |
$0.6 |
-$44 |
1.6 |
Feb-00 |
0.2 |
$24.00 |
$840 |
| DYAX CORP. |
$5.59 |
57% |
-27% |
$212 |
$59 |
$10 |
$163 |
$1.5 |
-$32 |
1.9 |
Aug-00 |
0.4 |
$15.00 |
$295 |
| ISIS PHARMACEUTICALS |
$5.05 |
76% |
3% |
$291 |
$47 |
$254 |
$498 |
$1.1 |
-$79 |
0.6 |
May-91 |
0.5 |
$10.00 |
$104 |
| LIGAND PHARMACEUTICALS |
$10.14 |
41% |
1% |
$750 |
$77 |
$174 |
$847 |
$1.8 |
-$27 |
2.8 |
Nov-92 |
1.2 |
$8.27 |
$131 |
| NEUROGEN CORP. |
$6.88 |
66% |
7% |
$238 |
$127 |
$13 |
$124 |
$0.8 |
-$36 |
3.6 |
Oct-89 |
1.1 |
$6.00 |
$35 |
| REGENERON PHARMACEUTICALS |
$9.49 |
89% |
9% |
$533 |
$312 |
$200 |
$421 |
$6.6 |
-$108 |
2.9 |
Apr-91 |
0.4 |
$22.00 |
$330 |
| SENOMYX |
$17.03 |
75% |
89% |
$434 |
$29 |
$0 |
$405 |
$5.6 |
-$21 |
1.4 |
Jun-04 |
2.8 |
$6.00 |
$153 |
| Screening Average |
|
66% |
7% |
$388 |
$103 |
|
$380 |
$2.6 |
-$49 |
2.1 |
|
1.0 |
|
|
| Screening Median |
|
66% |
3% |
$291 |
$70 |
|
$405 |
$1.5 |
-$36 |
1.9 |
|
0.5 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/30/05
Close
|
% of 52wk
High |
% change since 9/30/04 |
Market Cap ($M) |
Liquidity Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/
Share At IPO |
IPO Post-Money Valuation ($M) |
| CARRINGTON LABORATORIES |
$4.21 |
57% |
14% |
$45 |
$2 |
$3 |
$47 |
$0.2 |
na |
na |
na |
na |
na |
na |
| CELLEGY PHARMACEUTICALS |
$1.43 |
26% |
-67% |
$43 |
$10 |
$0 |
$33 |
$1.6 |
na |
na |
Aug-95 |
0.2 |
$6.25 |
$24 |
| CURATIVE HEALTH SERVICES |
$0.97 |
13% |
-86% |
$13 |
$12 |
$5 |
$6 |
$0.0 |
-$19 |
0.6 |
Jun-91 |
0.1 |
$7.50 |
$74 |
| LIFECELL CORP. |
$21.63 |
85% |
116% |
$694 |
$48 |
$0 |
$646 |
$3.7 |
na |
na |
Feb-92 |
2.8 |
$7.75 |
$27 |
| LIFECORE BIOMEDICAL |
$12.09 |
65% |
73% |
$158 |
$35 |
$5 |
$128 |
$0.6 |
na |
na |
na |
na |
na |
na |
| Wound Average |
|
49% |
10% |
$190 |
$21 |
|
$172 |
$1.2 |
-$19 |
0.6 |
|
1.0 |
|
|
| Wound Median |
|
57% |
14% |
$45 |
$12 |
|
$47 |
$0.6 |
-$19 |
0.6 |
|
0.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Overall Average |
|
67% |
10% |
$1,589 |
$171 |
|
$1,514 |
$4.2 |
-$42 |
3.5 |
|
3.5 |
|
|
| Overall Median |
|
69% |
-3% |
$276 |
$56 |
|
$224 |
$1.9 |
-$28 |
1.8 |
|
0.9 |
|
|
originally published 10/07/2005 |